Shares of Humana Inc. (HUM) soared 11.27% on Friday, closing at $274.96, as investor sentiment shifted positively across the managed-care sector. The rally was fueled by CVS Health's decision to lift its 2026 profit outlook, citing improved medical cost control within its Aetna unit. This move reignited interest in Medicare Advantage stocks, with Humana leading the charge.
The stock's sharp advance followed a close of $247.12 on Thursday. CVS's announcement on Wednesday that it expects stronger 2026 earnings due to tighter reins on medical expenses provided a tailwind for the entire group. UnitedHealth Group and Elevance Health also posted modest gains, keeping the spotlight on the sector.
Humana's first-quarter results, released earlier, showed revenue climbing to $39.65 billion from $32.11 billion year-over-year, driven by increased Medicare Advantage membership and higher premiums. However, adjusted earnings dropped to $10.31 per share from $11.58, and GAAP EPS fell to $9.83. The insurance segment benefit ratio stood at 89.4%, a key metric indicating the portion of premiums used for medical care.
Despite the strong top-line performance, Humana's 2026 outlook remains under pressure. The company maintained its full-year adjusted earnings forecast of at least $9 per share but trimmed its GAAP guidance to no less than $8.36, down from $8.89. Lower Medicare Star Ratings—quality grades that determine bonus payments—and limited funding are key headwinds. CEO Jim Rechtin described the quarter as a "solid start to the year," highlighting improvements in customer experience and care quality.
The rally has not alleviated all concerns. Analysts at Cantor Fitzgerald noted "signals that the back-half of the year could be difficult to manage," while Morningstar's Julie Utterback suggested investors may have expected a more ambitious 2026 outlook given the strong start. Humana continues to flag a gap between Medicare Advantage payment rates and actual care costs, with the discrepancy widening compared to last year.
On the regulatory front, the Centers for Medicare & Medicaid Services projected a 2.48% average increase in 2027 Medicare Advantage payments, translating to over $13 billion in additional funding. This is a significant improvement from the earlier 0.09% estimate. However, Humana's options remain limited. If medical utilization rises later this year or benefit reductions hurt enrollment, Friday's gains could prove temporary. The company has indicated it will adjust benefits if needed to protect margins.
CVS's updated outlook added another dimension, with CFO Brian Newman citing improved forecasting accuracy. Leerink's Michael Cherny labeled CVS's quarter "very strong." Still, Humana's near-term trajectory hinges on cost trends and regulatory developments, making the stock a key watch for investors focused on the managed-care space.
